Black Hills Regional Eye Institute | Rapid City, SD

Research site

(Unclaimed)

Location

2800 Third Street, Rapid City, South Dakota, United States of America

Site insights

Top conditions

Top treatments

Aflibercept

Ranibizumab

KSI-301

Triamcinolone Acetonide

Pegcetacoplan

AR-12286

APL-2

Abicipar Pegol

Rebamipide

RGN-259

Parent organization

This site is a part of Black Hills Regional Eye Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 72 total trials

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)

Enrolling

Neurotrophic Keratopathy

Drug: Placebo

Drug: RGN-259

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting

Age-Related Macular Degeneration

Geographic Atrophy

Drug: avacincaptad pegol

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained rele...

Active, not recruiting

Open-Angle Glaucoma

Ocular Hypertension

Drug: Bimatoprost (SR)

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling

Wet Age-related Macular Degeneration

Wet AMD

Genetic: RGX-314

Biological: Ranibizumab (LUCENTIS®)

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma (VENICE)

A study of the Streamline Surgical System versus competitor

Enrolling

Open Angle Glaucoma

Device: Streamline Surgical System

Device: iStent Inject W

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) i...

Active, not recruiting

Neovascular Age-Related Macular Degeneration

Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)

Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)